[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transplant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transplant":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,54,85,110,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":35,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100410565","early-phase-1-concomitant-renal-and-urinary-bladder-allograft-transplantation-100410565",false,"NCT04626167","Concomitant Renal and Urinary Bladder Allograft Transplantation","Inclusion Criteria:\n\n* Male or female patients between 1 yr. and 60 years of age.\n* Subject is willing and able to give signed informed consent, or have a legally authorized representative who is willing and able to give consent. Informed assent will be required for children 6-17 years of age as appropriate or warranted.\n* Patients with CKD secondary to neurogenic bladder, lower urinary tract obstruction or other disorders of the urinary bladder.\n* Medical need for a bladder transplant, as defined by the presence of exhibiting \"hostile bladders\" defined as end filling pressure or detrusor leak point pressure (DLPP) of or greater than 40 cm H20 or at below estimated bladder capacity for age, or detrusor overactivity with detrusor sphincter dyssynergia, or new onset of upper urinary tract changes (hydronephrosis, vesicoureteral reflux) in the last 12 months\n* If a concomitant kidney transplant is being considered, additionally, estimated GFR less than or equal to 20 mL\u002Fmin or dialysis. If GFR 20-25 mL\u002Fmin would also qualify if expected progression is rapid (\\>10 mL\u002Fmin\u002Fyear)\n* Vetting and approval by the Mayo Clinic multidisciplinary transplant team (MDC) for renal transplantation.\n* Ability of subject and\u002For care provider to be successfully trained in clean intermittent catheterization and bladder cycling. Or current use of CIC.\n* Utilization of maximally-tolerated dose and regimen of medical therapy (e.g. anticholinergics) or failure to tolerate\u002Fcontraindications to such agents.\n* Psychosocial clearance: Demonstrated commitment to psychological evaluation perioperatively, in which the psychologist must confirm that the subject has the maturity and stable psychosocial environment necessary for this research study.\n* Agree to avoid pregnancy for 1 year after surgery through abstinence or approved contraception as noted in Appendix A (female subjects only)\n* If patient has a history of malignancy (with the exception of localized non-melanoma skin cancer) the patient must be at least 5 years from termination of treatment without evidence of recurrent disease.\n\nExclusion Criteria:\n\n* They are pregnant or breastfeeding, or planning a pregnancy during the course of the study, or who are of child bearing potential and not willing to continue using an effective method of birth control (i.e. with a low failure rate of less than 1 percent per year including injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence, or a vasectomized partner), or\n* Any contraindication to general anesthesia or evaluation reveals that the subject cannot safely undergo general anesthesia and post-operative recovery due to severe cardiovascular, pulmonary, neurological, metabolic, or rheumatologic disease (requires special consultation)\n* Any contraindication or known anaphylactic or severe systemic reaction to either human blood products or materials of bovine origin\n* Subjects with a current positive (\\>=5 mm induration for high-risk subjects; otherwise \\>=10 mm of induration) purified protein derivative (PPD) test are excluded unless they have completed a full course of treatment for latent TB and have a negative chest x-ray film at enrollment.\n* Known history of hypersensitivity to aminoglycosides or fluoroquinolones\n* Use of any investigational product within 3 months\n* Prior participation in the study\n* Currently smoking\n* Current incarceration for any reason\n* Unwillingness, inability, or unlikely compliance of individual and\u002For primary caregiver with study related schedules procedures, management, or follow -up in the opinion of the PI and\u002For co-investigators\n* Any circumstance in which the investigator deems participation in the study is not in the subject's best interest\n* Subjects with an ALT or AST value \\>3 times the upper limit of normal\n* Subjects with acute or chronic abdominal skin infections and\u002For acute or chronic abdominal inflammatory conditions such as inflammatory bowel disease\n* Subjects with uncontrolled diabetes defined as HgA1c\\>10, unstable cardiac and\u002For pulmonary disorders, or bleeding disorders\n* Active malignant neoplasm (with the exception of localized non-melanoma skin cancer) that is untreated, unresponsive to available treatment, or too recently treated to determine relapse risk.\n* Surgical procedure for transplantation cannot be successfully performed for anatomical reasons\n* Life expectancy with successful transplantation is estimated to be \\\u003C5 years for any reason.\n* There is any other disease, physical examination finding, or clinical laboratory result that provides a reasonable suspicion of a disease or condition that contraindicates the procedure or the interpretation of results or render the subject at high risk for treatment complications, or\n* Serious or uncontrolled psychiatric illness or disorder that could compromise their understanding of, or compliance with, follow-up visits\u002Fcare after transplant, or\n* Taking medications on specified hourly intervals that may be affected by changes to renal clearance, or\n* Hypertension stage II \\> 99th percentile, unless they had a complete workup to exclude secondary etiologies other than being overweight, or\n* Presence of severe coagulopathy, (hyper or hypo)\n* Patient is not up to date on current CDC recommended vaccines","ALL","1 Year","60 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","The purpose of this study is to establish if concomitant renal and vascularized urinary bladder allograft transplantation is feasible.",[26,27,28,29,30,31,32,33,34],"Chronic Kidney Diseases","Bladder Dysfunction","Bladder Absence","Posterior Urethral Valve","Neurogenic Bladder","Bladder Exstrophy","Bladder Outlet Obstruction","Failure, Kidney","Transplant",[36,37,38,39,40],"Urinary Bladder Transplant","Bladder Transplant","Bladder Augment","Neobladder","Ileocystoplasty","RECRUITING","2026-04-20",{"date":44,"type":45},"2026-04-23","ACTUAL",{"date":47,"type":45},"2021-06-01",{"date":49,"type":20},"2026-08",{"name":51,"class":52},"Mayo Clinic","OTHER",2,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":15,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":53},"100392492","optimizing-y90-therapy-for-radiation-lobectomy-100392492","NCT04390724","Optimizing Y90 Therapy for Radiation Lobectomy","Yttrium-90 Radiation Lobectomy: Dose Optimization and Prediction of FLR Hypertrophy to Enable Resection of HCC","Inclusion Criteria:\n\n1. Patients must have been diagnosed with HCC confirmed by histology or must meet one of the following American Association for the Study of Liver Diseases (AASLD) guidelines:\n\n   * AFP \\>200 and radiological evidence (arterial hypervascularity) of lesion \\> 2 cm does not require biopsy\n   * Two imaging modalities (triphasic CT, MRI, ultrasound, angiography) demonstrating arterial hypervascularity in the background of cirrhosis does not require biopsy\n   * One imaging modality with a lesion with arterial hypervascularity with wash out in early or delayed venous phase, does not require a biopsy\n2. Child-Pugh stage A\n3. Future Liver Remnant (FLR) of \\\u003C 40%\n4. ECOG Performance Status 0-1\n5. Bilirubin ≤ 3.0 mg\u002Fdl- Treatment may proceed if the Bilirubin is elevated if the tumor may be isolated from a vascular standpoint\n6. Creatinine ≤ 2.0 mg\u002Fdl\n7. ANC ≥ 1.5 K\u002FuL\n8. Platelets \\> 25 K\u002FuL\n9. Patient is willing participate in this study and has signed the consent\n10. For Group 2 patients only:\n\n    * Patients planned Y90 dose and embolic load is found to fall within the optimal dose and embolic load size from data from Group 1 patients\n\nExclusion Criteria:\n\n1. Patient must not be pregnant\n\n   NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n   * Has not undergone a hysterectomy or bilateral oophorectomy\n   * Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \\> 12 months)\n2. For Patients in Group 2 only:\n\n   * Patients who have contraindications to MRI:\n\n     * Patients that are claustrophobic and haven't been able to tolerate an MRI in the past. (Patients with mild claustrophobia are eligible and have the option to take\n\n       1mg oral Lorazepam prior to the MRI, if needed)\n     * Allergy to gadolinium-containing contrast media\n     * Patients with a pacemaker, metallic clip, aneurysm clips, shrapnel fragments, etc.\n     * Patients with an eGFR \\\u003C 30 mL\u002Fmin\u002Fm²\n3. Must not have any significant life-threatening extra-hepatic disease or life- threatening secondary malignancies, including patients who are on dialysis, have unresolved diarrhea, have serious unresolved infections including patients who are known to be HIV positive or have acute HBV or HCV\n4. Must not have any contraindications to angiography and selective visceral catheterization such as bleeding diathesis or coagulopathy that is not correctable by usual therapy of hemostatic agents (e.g. closure device)\n5. Must not have any co-morbid disease or condition that would place the patient at undue risk and preclude safe use of TheraSphere treatment, in the Investigator's judgment\n6. History of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically\n\n   \\-","18 Years",{"count":63,"type":20},104,"OBSERVATIONAL","HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care. The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1.",[67,68,34,69,70],"HCC","Resection","Metastatic Cancer","Adult Primary Liver Cancer",[67,72,73,74,75],"Y90 Radioembolization","Liver Resection","Liver Transplant","Liver Cancer","2026-03-23",{"date":78,"type":45},"2026-03-27",{"date":80,"type":45},"2020-07-17",{"date":82,"type":20},"2026-07",{"name":84,"class":52},"Northwestern University",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":15,"minAge":61,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100494412","simultaneous-prospective-kidney-transplant-assessment-in-combined-liver-kidney-candidates-100494412","NCT05717842","Simultaneous Prospective Kidney Transplant Assessment in Combined Liver Kidney Candidates","Simultaneous Prospective Kidney Transplant Assessment in Combined Liver Kidney","RECOVERY","Inclusion Criteria:\n\n1. \\> 18 years old\n2. Listed for Liver Transplant for ESLD and Kidney Transplant (not on dialysis at time of transplant surgery)\n3. Candidates with two native kidneys.\n4. Willing to participate and sign informed consent form.\n\nExclusion Criteria:\n\n1. Unstable patients (e.g. in the ICU or those who are on Continuous Renal Replacement Therapy (CRRT) who cannot complete the nuclear medicine scan or those with AKI on Hemodialysis\n2. Prior history of any solid organ transplant.\n3. Those who are currently pregnant or breast feeding.\n4. Patients who have Autosomal Dominant polycystic kidney disease",{"count":94,"type":20},15,"The purpose of the study is to determine how much a persons kidney function recovers after receiving a simultaneous liver kidney transplant. The investigators will be contacting patients with kidney dysfunction with estimated GFR between 25 and 40 (not on dialysis treatment) who are listed to receive a simultaneous liver kidney (SLK) transplant to look at this function recovery. The investigators hope to develop a criteria based on GFR measurement, kidney function calculations from native kidneys vs transplanted kidney and compare the contributions, and correlate with estimated GFR on basic metabolic panel (BMP: a blood test) to predict higher chances of recovery of native kidney function.",[34],[98,99],"Liver","Kidney","2026-03-10",{"date":102,"type":45},"2026-03-12",{"date":104,"type":45},"2023-12-08",{"date":106,"type":20},"2027-02",{"name":108,"class":52},"Indiana University",1,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":15,"minAge":61,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":109},"100376521","donor-outcomes-following-hand-assisted-and-robotic-living-donor-nephrectomy-a-retrospective-review-100376521","NCT04182607","Donor Outcomes Following Hand-Assisted and Robotic Living Donor Nephrectomy: a Retrospective Review","Inclusion Criteria:\n\n* ≥ 18 years of age\n* Kidney donors and recipients who underwent a hand-assisted or robotic kidney transplant\n\nExclusion Criteria:\n\n* Patients that do not meet the Study Inclusion Criteria laid out above",{"count":117,"type":20},240,"1.1. Background: Renal transplantation is the treatment of choice for eligible patients with end-stage renal disease. It provides better outcomes in terms of life expectancy and quality of life than dialysis (Liu, Narins, Maley, Frank, \\& Lallas, 2012). Kidney transplants from living donors also have additional benefits in terms of graft function and survival compared to transplants from cadaver donors (Galvani et al., 2012). Living donor transplants provide an opportunity to have good quality grafts and to perform the procedure when the recipient is in an optimal clinical status (Creta et al., 2019).\n\nLaparoscopic donor nephrectomy was first introduced in 1995 and is currently accepted as the gold standard for kidney procurement from living donors. The first worldwide robotic assisted laparoscopic donor nephrectomy was performed in 2000 by Horgan et al. (Horgan et al., 2007).\n\nThe main obstacle to living donation is the exposure of a healthy subject to the risks of a major surgical intervention. Therefore, efforts have been made to reduce complications and postoperative pain, achieve faster recovery, and minimize the surgical incisions.\n\nMinimally invasive procedures like hand-assisted and robotic approaches greatly enhance living donation rates, and in 2001 the number of living donors exceeded the number of cadaver donors (Horgan et al., 2007).\n\n1.2. Aim(s)\u002FObjective(s): The objective of this study is to compare intra- and postoperative patient outcomes of kidney donors following hand-assisted and robotic kidney transplants at a single center.\n\n1.3. Rationale for the study: More research is needed regarding the differences between minimally invasive approaches to kidney transplantation.",[34,120],"Kidney Diseases",[122,123,124],"kidney","transplant","nephrectomy","2024-11-18",{"date":127,"type":45},"2024-11-20",{"date":129,"type":45},"2019-11-06",{"date":131,"type":20},"2025-11",{"name":133,"class":52},"Methodist Health System",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":15,"minAge":61,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":21,"phases":145,"briefSummary":147,"conditions":148,"keywords":154,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":4},"100512344","liver-transplantation-after-ex-vivo-liver-perfusion-100512344","NCT05951231","Liver Transplantation After ex Vivo Liver Perfusion","Liver Transplantation After ex Vivo Liver Perfusion - The EVOLVE Study","EVOLVE","Inclusion Criteria:\n\n* Signed informed consent\n* ≥ 18 years\n* Indication for liver transplantation (one criteria must be met):\n* Colorectal cancer patients who have received 1st and 2nd line chemotherapy where the treatment has been stopped due to progression or toxicity and the patient is not eligible for SECA-2 (Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases) study.\n* Hepatocellular carcinoma patients who are not suitable for standard liver transplantation, liver resection or local treatment (Transarterial Chemoembolisation or Selective internal radiotherapy). The patients must have progression or intolerance (toxicity) for immune checkpoint inhibitors or 1st line treatment.\n* Cholangiocarcinoma patients who have progression or intolerance to first-line chemotherapy.\n* Benign liver disease with urgent need for transplantation within months, but no regular graft is available.\n* Life expectancy ≤ 6 months\n* Willing, able and expected cooperation to attend follow-up examinations\n* Patients who have a need for liver transplantation but cannot participate in other transplant studies or participation in another clinical trial with randomization to liver transplantation.\n\nFor malignant disease the following criteria must be met:\n\n* Good performance status assessed at the discretion of the treating physician.\n* ECOG (Eastern Cooperative Oncology Group) 0 or 1\n* Satisfactory blood tests\n\n  * Hemoglobin \\>8 g\u002Fdl\n  * Neutrophiles \\>1.0 (after any Granulocyte colony-stimulating factor)\n  * Platelets \\>75\n  * Bilirubin \\\u003C1.5 x upper normal level\n  * ASAT (Aspartate aminotransferase), ALAT (alanine aminotransferase) \\\u003C5 x upper normal level\n  * Albumin above lower normal level.\n\nExclusion Criteria:\n\n* Already listed for ordinary Ltx with expectance of getting offered a regular liver graft within a reasonable time-frame.\n* Patients included in the control arm of the SECA-3 study or the Excalibur studies except for the Ltx arm of the Excalibur I study.\n* Mental conditions rendering the subject incapable to understand the nature, scope, and consequences of the trial.\n* Any reason why, in the opinion of the investigator, the patient should not participate.","100 Years",{"count":144,"type":20},22,[146],"NA","Today, it is difficult to predict liver function after transplantation and therefore livers where poor function is assumed (marginal livers) become discarded. The study aim is to increase the number of available donor livers, especially for liver cancer patients, by pre-treating and testing marginal ones (extended criteria donor (ECD) livers) liver on a liver perfusion machine. A liver perfusion machine can simulate liver transplantation and enables functional\u002Fquality testing before transplantation. The machine will hopefully also make marginal livers more functional by reducing ischemia- \\& reperfusion injury. A marginal donor liver is perfused ex situ with oxygenated blood from a blood donor on a machine. The liver can be tested here for function using internationally recognized criteria. At the same time, the investigators will carry out analyzes with microdialysis which can give a better picture of organ function and damage. Additionally, various samples of the liver and perfusate will be collected. Liver that achieves criteria for transplantation will be offered to the recipient.",[149,150,151,152,34,153,75],"Liver Transplant; Complications","Transplant; Failure, Liver","Transplant Dysfunction","Transplant; Complication, Rejection","Liver Metastases",[98,155,156,157,158,159,160],"Transplantation","Perfusion","Dual-end-ischemic Hypothermic Oxygenated Perfusion","Normothermic Machine Perfusion","Controlled Oxygenated Rewarming","Microdialysis","NOT_YET_RECRUITING","2023-10-31",{"date":164,"type":45},"2023-11-01",{"date":166,"type":20},"2024-02",{"date":168,"type":20},"2029-02",{"name":170,"class":52},"Oslo University Hospital"]